Paul S Shipman Net Worth

The estimated Net Worth of Paul S Shipman is at least 20.6 千$ dollars as of 15 August 2003. Paul Shipman owns over 6,000 units of Hookipa Pharma Inc stock worth over 6,864$ and over the last 21 years Paul sold HOOK stock worth over 13,740$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Paul Shipman HOOK stock SEC Form 4 insiders trading

Paul has made over 1 trades of the Hookipa Pharma Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Paul sold 6,000 units of HOOK stock worth 13,740$ on 15 August 2003.

The largest trade Paul's ever made was selling 6,000 units of Hookipa Pharma Inc stock on 15 August 2003 worth over 13,740$. On average, Paul trades about 3,000 units every 0 days since 2003. As of 15 August 2003 Paul still owns at least 1,300 units of Hookipa Pharma Inc stock.

You can see the complete history of Paul Shipman stock trades at the bottom of the page.

What's Paul Shipman's mailing address?

Paul's mailing address filed with the SEC is 14300 NE 145TH STREET, SUITE 210, , WOODINVILLE, WA, 98072.

Insiders trading at Hookipa Pharma Inc

Over the last 21 years, insiders at Hookipa Pharma Inc have traded over 12,222,300$ worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth 18,573,557$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Bros. Advisors Lp Baker Bro...、Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of 180,581$. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth 5,110$.

What does Hookipa Pharma Inc do?

hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a

Complete history of Paul Shipman stock trades at Hookipa Pharma Inc

Hookipa Pharma Inc executives and stock owners

Hookipa Pharma Inc executives and other stock owners filed with the SEC include:

• Joern Aldag,
  Chief Executive Officer, Director
• Reinhard Kandera,
  Chief Financial Officer, Director
• Igor Matushansky,
  Chief Medical Officer and Global Head of Research and Development
• Joern Aldag,
  CEO & Director
• Dr. Igor Matushansky M.D., Ph.D.,
  Chief Medical Officer and Global Head of R&D
• Dr. Reinhard Kandera,
  CFO & Director
• Sander van Deventer,
  Independent Director
• Graziano Seghezzi,
  Independent Director
• Jan van de Winkel,
  Independent Chairman of the Board
• Michael Kelly,
  Independent Director
• David Kaufman,
  Independent Director
• Christoph Lengauer,
  Independent Director
• Julie O Neill,
  Independent Director
• Jean-Charles Soria,
  Director
• Roman Necina,
  Chief Technology Officer
• Klaus Orlinger,
  Executive Vice President - Research
• Dr. Klaus Orlinger Ph.D.,
  Exec. VP of Research
• Nina Waibel,
  Sr. Director of Communications
• Marine Popoff,
  Communications & Investor Relations Mang.
• Dr. Roman Necina Ph.D.,
  Chief Technology Officer
• Lukas Flatz,
  Co-Founder
• Andreas Bergthaler,
  Co-Founder
• Prof. Rolf M. Zinkernagel M.D., Ph.D.,
  Co-Founder
• Jerry D Jones,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Capital Fund Ii Cooperatief...,
  10% owner
• David Pinschewer,
  Chief Scientific Officer
• Group, Llc Green Jeremy Red...,
  
• Capital Vi Fcpr Sofinnova P...,
  
• Anders Lilja,
  Sr. VP, Technical Development
• Timothy P. Reilly,
  
• Andrew R Goeler,
  Director
• Mark D Moreland,
  Chief Financial Officer
• John D Jr Rogers,
  Director
• Martin J Iv Wall,
  Vice President, Sales
• David R Lord,
  Director
• V Sebastian Pastore,
  VP, Brewing Operations & Tech
• Marc J Cramer,
  Director
• Terry E Michaelson,
  Co-Chief Executive Officer
• Kurt R Widmer,
  Director
• Danielle A Katcher,
  Vice President, Marketing
• Kevin R Kelly,
  Director
• Timothy P Boyle,
  Director
• David J Mickelson,
  President & COO
• Companies, Inc.Busch Invest...,
  
• Frank H Clement,
  Director
• Ann G Widmer,
  10% owner
• Anthony J Short,
  Director
• Kurt R Widmer Ann G Widmer,
  
• Paul S Shipman,
  President & CEO
• Michael Loughran,
  Director
• Katia Schlienger,
  Chief Medical Officer
• Jorn Aldag,
  Chief Executive Officer
• Christine D. Baker,
  Chief Operating Officer
• Mark Winderlich,
  Chief Development Officer
• Mary Theresa Coelho,
  EVP and CFO
• Malte Peters,
  Chief Executive Officer
• Sean A Cassidy,